U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Target cells

MedGen UID:
526211
Concept ID:
C0221284
Cell
Synonyms: Bell-shaped erythrocyte (in vivo); Codocyte; Codocytes; Leptocyte; Target cell
SNOMED CT: Target cell (112660002); Codocyte (112660002); Bell-shaped erythrocyte (in vivo) (112660002); Leptocyte (259686006)
 
HPO: HP:0034280

Definition

Target cells (codocytes) have a centrally located disk of hemoglobin surrounded by an area of pallor with an outer rim of hemoglobin adjacent to the cell membrane giving the cell the appearance of a target. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVTarget cells

Conditions with this feature

Hb SS disease
MedGen UID:
287
Concept ID:
C0002895
Disease or Syndrome
Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections, primarily encapsulated organisms. Acute chest syndrome (ACS) is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation as well as activating pathways that contribute to the pathophysiology directly. Individuals with the highest rates of hemolysis are at higher risk for pulmonary artery hypertension, priapism, and leg ulcers and may be relatively protected from vaso-occlusive pain.
X-linked sideroblastic anemia with ataxia
MedGen UID:
335078
Concept ID:
C1845028
Disease or Syndrome
X-linked sideroblastic anemia and ataxia is a rare condition characterized by a blood disorder called sideroblastic anemia and movement problems known as ataxia. This condition occurs only in males.\n\nSideroblastic anemia results when developing red blood cells called erythroblasts do not make enough hemoglobin, which is the protein that carries oxygen in the blood. People with X-linked sideroblastic anemia and ataxia have mature red blood cells that are smaller than normal (microcytic) and appear pale (hypochromic) because of the shortage of hemoglobin. This disorder also leads to an abnormal accumulation of iron in red blood cells. The iron-loaded erythroblasts, which are present in bone marrow, are called ring sideroblasts. These abnormal cells give the condition its name. Unlike other forms of sideroblastic anemia, X-linked sideroblastic anemia and ataxia does not cause a potentially dangerous buildup of iron in the body. The anemia is typically mild and usually does not cause any symptoms.\n\nX-linked sideroblastic anemia and ataxia causes problems with balance and coordination that appear early in life. The ataxia primarily affects the trunk, making it difficult to sit, stand, and walk unassisted. In addition to ataxia, people with this condition often have trouble coordinating movements that involve judging distance or scale (dysmetria) and find it difficult to make rapid, alternating movements (dysdiadochokinesis). Mild speech difficulties (dysarthria), tremor, and abnormal eye movements have also been reported in some affected individuals.

Professional guidelines

PubMed

Cui X, Wang F, Liu C
Front Immunol 2023;14:1062045. Epub 2023 Jan 19 doi: 10.3389/fimmu.2023.1062045. PMID: 36742308Free PMC Article
Torres RP, Santos FP, Branco JC
ARP Rheumatol 2022 Oct 1;1(3):225-229. PMID: 35724450
Dastjerd NT, Valibeik A, Rahimi Monfared S, Goodarzi G, Moradi Sarabi M, Hajabdollahi F, Maniati M, Amri J, Samavarchi Tehrani S
Cell Biochem Funct 2022 Jan;40(1):28-48. Epub 2021 Dec 14 doi: 10.1002/cbf.3676. PMID: 34904722

Recent systematic reviews

Dżaman K, Czerwaty K, Reichert TE, Szczepański MJ, Ludwig N
Int J Mol Sci 2023 Jul 31;24(15) doi: 10.3390/ijms241512277. PMID: 37569652Free PMC Article
Adhikari R, Witwer KW, Wiberg KJ, Chen YC
J Leukoc Biol 2023 Mar 1;113(3):255-287. doi: 10.1093/jleuko/qiac021. PMID: 36802000
Glass GE
Aesthet Surg J 2023 Apr 10;43(5):NP357-NP371. doi: 10.1093/asj/sjad018. PMID: 36722207Free PMC Article
Rothschild-Rodriguez D, Causer AJ, Brown FF, Collier-Bain HD, Moore S, Murray J, Turner JE, Campbell JP
Exerc Immunol Rev 2022;28:1-35. PMID: 35452398
Kümler I, Tuxen MK, Nielsen DL
Cancer Treat Rev 2014 Mar;40(2):259-70. Epub 2013 Sep 11 doi: 10.1016/j.ctrv.2013.09.002. PMID: 24080156

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...